Elanco Animal Health (NYSE:ELAN) Updates Q3 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its third quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.190-0.220 for the period, compared to the consensus earnings per share estimate of 0.190. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.100-1.160 EPS.

Analysts Set New Price Targets

Several analysts have weighed in on ELAN shares. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Finally, TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.73.

Elanco Animal Health Price Performance

ELAN stock traded up $0.74 during trading on Wednesday, hitting $26.34. The company had a trading volume of 9,140,258 shares, compared to its average volume of 5,368,945. The firm has a market capitalization of $13.15 billion, a price-to-earnings ratio of -52.57, a P/E/G ratio of 1.68 and a beta of 1.67. The business has a 50 day moving average of $24.68 and a 200 day moving average of $24.09. Elanco Animal Health has a fifty-two week low of $13.76 and a fifty-two week high of $27.98. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts predict that Elanco Animal Health will post 1.11 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Elanco reported adjusted EPS of $0.34, above the $0.27 consensus and up from $0.26 a year earlier. Revenue rose 10% year over year to $1.368 billion, beating the $1.31 billion analyst estimate, while organic constant-currency growth was 8%. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year outlook was raised: Elanco now expects 2026 adjusted EPS of $1.10 to $1.16, above the $1.07 consensus. Revenue guidance was increased to $5.09 billion-$5.14 billion, representing 6%-7% organic constant-currency growth, and adjusted EBITDA guidance was raised to $1.01 billion-$1.035 billion. Elanco Animal Health Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Innovation and balance-sheet targets improved: The company raised its 2026 innovation-revenue target to $1.25 billion and lowered its year-end net-leverage target to approximately 3.0 times adjusted EBITDA, compared with 3.1 times at the end of the second quarter. Management also projects adjusted EPS growth of approximately 20% at the midpoint of its guidance. Elanco Animal Health Reports Second Quarter 2026 Results
• Neutral Sentiment: Third-quarter guidance was broadly in line: Elanco forecast adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion. The EPS range begins at the analyst consensus, limiting the near-term upside surprise compared with the full-year outlook. Elanco Animal Health Q2 Key Metrics

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. Compound Planning Inc. boosted its position in shares of Elanco Animal Health by 29.7% in the 4th quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock valued at $482,000 after purchasing an additional 4,876 shares during the period. Invesco Ltd. raised its holdings in Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after buying an additional 3,690,735 shares during the period. Corient Private Wealth LLC lifted its stake in Elanco Animal Health by 122.3% during the fourth quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock valued at $3,743,000 after buying an additional 90,993 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Elanco Animal Health by 29.0% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 78,610 shares of the company’s stock valued at $1,779,000 after buying an additional 17,657 shares in the last quarter. Finally, State of Tennessee Department of Treasury boosted its holdings in shares of Elanco Animal Health by 8.1% in the fourth quarter. State of Tennessee Department of Treasury now owns 146,658 shares of the company’s stock worth $3,532,000 after buying an additional 11,012 shares during the period. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.